Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 49

Results For "EMA"

3000 News Found

Bristol Myers Squibb prices €5 billion senior unsecured notes offering
News | November 10, 2025

Bristol Myers Squibb prices €5 billion senior unsecured notes offering

The offering is expected to close on November 10, 2025, subject to customary closing conditions


Relmada gains FDA backing for two registrational trials and reports 92% response with NDV-01 in bladder Cancer
Clinical Trials | November 10, 2025

Relmada gains FDA backing for two registrational trials and reports 92% response with NDV-01 in bladder Cancer

Relmada expects to initiate its Phase 3 program in the first half of 2026


Venus Remedies expands ASEAN presence with new drug approvals in Vietnam
News | November 10, 2025

Venus Remedies expands ASEAN presence with new drug approvals in Vietnam

Venus Remedies now has 29 active product approvals in Vietnam alone


Novo Nordisk India partners with Emcure to commercialise Poviztra in India
News | November 10, 2025

Novo Nordisk India partners with Emcure to commercialise Poviztra in India

Poviztra is a second brand of Wegovy


Syngene International reports Q2 FY26 consolidated PAT at Rs. 67.1 Cr
News | November 09, 2025

Syngene International reports Q2 FY26 consolidated PAT at Rs. 67.1 Cr

Syngene International has reported total income of Rs. 926 crore during the period ended September 30, 2025


Lupin Bioresearch Center receives zero observations from USFDA
Drug Approval | November 08, 2025

Lupin Bioresearch Center receives zero observations from USFDA

A bio-analytical Remote Regulatory Assessment was also conducted from October 30 to November 7, 2025, and concluded with no observations


Novo Nordisk’s new CEO doubles down on obesity, diabetes push despite mixed Q3
News | November 07, 2025

Novo Nordisk’s new CEO doubles down on obesity, diabetes push despite mixed Q3

Sales from Novo’s GLP-1 portfolio—including Wegovy for obesity and Ozempic for type 2 diabetes reached $5.6 billion


Pfizer reports Q3 vaccine sales decline amid challenging US market conditions
News | November 07, 2025

Pfizer reports Q3 vaccine sales decline amid challenging US market conditions

Comirnaty, Pfizer’s COVID-19 prevention vaccine, reported global sales of $1.15 billion